Organon and Samsung Bioepis Expand Agreement to Commercialize PYZCHIVA® (ustekinumab), a Biosimilar Referencing STELARA® (ustekinumab) in Canada
Organon expanded its partnership with Samsung Bioepis to secure exclusive commercialization rights in Canada for PYZCHIVA, a biosimilar referencing STELARA. The agreement adds a sixth product to the companies' Canadian collaboration portfolio, which covers therapeutic areas including immunology and oncology.
Key figures
- Launch year
- 2026
- Canada collaboration product count
- 6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.